TITLE

The global cardiovascular drug market

AUTHOR(S)
Quirk, Jeremy; Maidwell, Nicola
PUB. DATE
April 2004
SOURCE
International Journal of Medical Marketing;Apr2004, Vol. 4 Issue 2, p96
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Presents an overview of the global cardiovascular drug market. Expectation of the growth of the value of the cardiovascular market in future; Dependence of the size and shape of the cardiovascular market on strong and often opposing forces; Definition and treatment of the cardiovascular disease in terms of individual risk factors; Dependency of a drug's success in the cardiovascular market on the ability to improve patient health.
ACCESSION #
12483820

 

Related Articles

  • Ticagrelor was more effective than clopidogrel in acute coronary syndromes with planned invasive treatment. Brophy, James M. // ACP Journal Club;5/18/2010, Vol. 152 Issue 5, p3 

    The article reports on a study that discusses safety and efficiency of ticagrelor and clopidogrel in patients with planned invasive management of an acute coronary syndrome (ACS). As stated, based on a secondary analysis of randomized controlled trial, thousands of patients were admitted for an...

  • Nateglinide does not reduce CV events in patients with impaired glucose tolerance.  // JAAPA: Journal of the American Academy of Physician Assistants (;Jun2010, Vol. 23 Issue 6, p54 

    The article reports on a study which found that nateglinide does not prevent cardiovascular (CV) events in patients with impaired glucose tolerance.

  • Comparative Effectiveness of Generic and Brand-Name Statins on Patient Outcomes. Gagne, Joshua J.; Choudhry, Niteesh K.; Kesselheim, Aaron S.; Polinski, Jennifer M.; Hutchins, David; Matlin, Olga S.; Brennan, Troyen A.; Avorn, Jerry; Shrank, William H. // Annals of Internal Medicine;9/16/2014, Vol. 161 Issue 6, p400 

    Background: Statins are effective in preventing cardiovascular events, but patients do not fully adhere to them. Objective: To determine whether patients are more adherent to generic statins versus brand-name statins (lovastatin, pravastatin, or simvastatin) and whether greater adherence...

  • The appropriate clinical use of niacin in the treatment of dyslipidemia. Houston, Mark; Guarneri, Mimi; Kahn, Joel // Clinical Lipidology;Feb2015, Vol. 10 Issue 1, p17 

    The authors discuss the results of a study which examined the use of niacin to treat dyslipidemia and cardiovascular disease (CVD). They emphasize the effectiveness of niacin for treating defined types of dyslipidemia and reducing CVD in addition to having a low incidence of adverse effects....

  • Sex differences in the effectiveness of statins after myocardial infarction. Karp, Igor; Chen, Shun-Fu; Pilote, Louise // CMAJ: Canadian Medical Association Journal;1/30/2007, Vol. 176 Issue 3, p333 

    Background: We sought to investigate the sex differences in the effectiveness of statins in patients with acute myocardial infarction (AMI). Methods: Linking hospital discharge and drug claims databases from Quebec, Canada (1998–2004), we identified statin users (n = 14 710) and non-users...

  • Adverse cardiovascular response to oral trimeprazine in children. Loan, W.H.; Cuthbert, D. // British Medical Journal (Clinical Research Edition);5/25/1985, Vol. 290 Issue 6481, p1548 

    Examines the adverse cardiovascular response to oral trimeprazine in children. Utilization of trimeprazine as premedicant and general pediatric sedative; Absence of hypotensive complications; Factors arising from preanesthetic sedatives.

  • AJPCPD.  // Australian Journal of Pharmacy;Jul2012, Vol. 93 Issue 1106, p91 

    A quiz related to cardiovascular disease and role of statins and diet in its treatment is presented.

  • CHD patients should take statins at night.  // Pulse;11/18/2002, Vol. 62 Issue 44, p4 

    Focuses on the impact of taking statin at night on the cholesterol-lowering effect of coronary heart disease patients.

  • Starting statins for primary prevention of cardiovascular disease. Tunstall-Pedoe, Hugh // Heart;Nov2013, Vol. 99 Issue 21, p1547 

    An introduction to the journal is presented in which the editor discuss the prevention of cardiovascular diseases by prescription of statins, drugs that lower cholesterol levels, in general population.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics